https://www.selleckchem.com/products/tp-0903.html
After adjustment for baseline differences, the primary outcome was not significantly different between patients with LVO and those without LVO (15% vs 16%, respectively; hazard ratio 0.83; 95% confidence interval 0.19 to 3.72; p = 0.809). In conclusion, in patients undergoing TAVI, concomitant LVO was relatively uncommon and occurred more often at mid-LV. The presence of pre-TAVI LVO was not associated with worse outcomes defined as increase all-cause mortality or HHF at 1-year.The ubiquitin-proteasome system (UPS) is composed of E1 ubi
Like
Comment
Share
